Fig. 6From: Canagliflozin for Japanese patients with chronic heart failure and type II diabetesPharmacological effects of canagliflozin suggested by the findings of this study. HbA1c hemoglobin A1c, LDL low-density lipoprotein cholesterol, HDL high-density lipoprotein cholesterol, TG triglyceride, ANP atrial natriuretic peptide, BNP brain natriuretic peptide, RAAS renin–angiotensin–aldosterone system, LVM left ventricular mass, LV left ventricularBack to article page